Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 19/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.53 |
| ▸ | SIK1 | P57059 | 1/20 | 0.41 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.41 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31483062 | 0.85 | PIK3CG (0.67) | PIK3CGPIK3CDPIK3CBPIK3CA | |
| SCHEMBL31483095 | 0.84 | PIK3CG (0.62) | PIK3CGPIK3CDPIK3CBPIK3CASIK1 | |
| SCHEMBL31483060 | 0.84 | PIK3CG (0.62) | PIK3CGPIK3CDPIK3CBPIK3CASIK1 | |
| SCHEMBL31483036 | 0.83 | PIK3CG (0.65) | PIK3CGPIK3CDPIK3CBPIK3CA | |
| SCHEMBL31483092 | 0.83 | PIK3CG (0.65) | PIK3CGPIK3CDPIK3CBPIK3CA | |
| SCHEMBL31483073 | 0.83 | PIK3CG (0.65) | PIK3CGPIK3CDPIK3CBPIK3CA | |
| SCHEMBL31483008 | 0.83 | PIK3CG (0.65) | PIK3CGPIK3CDPIK3CBPIK3CA | |
| SCHEMBL31483156 | 0.81 | PIK3CG (0.71) | PIK3CGPIK3CDPIK3CBPIK3CA | |
| SCHEMBL31483057 | 0.81 | PIK3CG (0.71) | PIK3CGPIK3CDPIK3CBPIK3CA | |
| SCHEMBL31483159 | 0.80 | PIK3CG (0.70) | PIK3CGPIK3CDPIK3CBPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119841829-A | Compounds for the treatment of PI3K gamma mediated diseases and uses thereof | 中国科学院合肥物质科学研究院 | 2025-04-18 | — | — | CN | disclosed |